Kyprolis (Carfilzomib) is a cancer medicine that interferes with the growth and spread of cancer cells in the body.
Kyprolis is used to treat multiple myeloma. It is sometimes given in conjunction with other medicines when treating relapsed multiple myeloma.
Kyprolis is usually given after at least two other cancer medicines have been tried without success.
General dosage information for the active ingredient contained in Kyprolis:
Carfilzomib (intravenous powder for injection)
Please confirm that the medication forms on the dosage document(s) above are relevant for the specific drug you are interested in.
Not all side effects for Kyprolis may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA.
For the Consumer
Applies to carfilzomib: intravenous powder for solution
In addition to its needed effects, some unwanted effects may be caused by carfilzomib (the active ingredient contained in Kyprolis). In the event that any of these side effects do occur, they may require medical attention.